In an interesting debate session at the European Atherosclerosis Society (EAS) 2022, Michal Vrablík, Czech Republic, and Ulrich Laufs, Germany, argued whether oral lipid-lowering therapies such as statins and ezetimibe are sufficient for cardiovascular disease (CVD) prevention or whether we need the support of injectables, i.e, proprotein convertase subtilisin/kexin type...